MODERN CHINESE MEDICINE GROUP CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3 HKD | -1.64% |
|
-6.25% | -11.76% |
| 03-22 | Modern Chinese Medicine Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-13 | Modern Chinese Medicine Warns of Up to 48% Profit Slump | MT |
| Sales 2021 | 361M 49.78M 390M 68.05M | Sales 2022 | 400M 55.16M 432M 75.4M | Capitalization | 291M 40.22M 315M 54.99M |
|---|---|---|---|---|---|
| Net income 2021 | 81M 11.18M 87.51M 15.28M | Net income 2022 | 87M 12.01M 93.99M 16.41M | EV / Sales 2021 | 0.62 x |
| Net cash position 2021 | 176M 24.25M 190M 33.15M | Net cash position 2022 | 282M 38.9M 305M 53.18M | EV / Sales 2022 | 0.02 x |
| P/E ratio 2021 |
4.85
x | P/E ratio 2022 |
3.32
x | Employees | 191 |
| Yield 2021 |
2.04% | Yield 2022 |
-
| Free-Float | 33% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.64% | ||
| 1 week | -6.25% | ||
| Current month | -18.92% | ||
| 1 month | -16.67% | ||
| 3 months | -11.76% | ||
| 6 months | -26.83% | ||
| Current year | -11.76% |
1 week
0.30
0.32
1 month
0.300.37
Current year
0.290.42
1 year
0.290.53
3 years
0.291.22
5 years
0.291.40
10 years
0.291.40
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Li Zhang
CEO | Chief Executive Officer | 59 | 19-12-11 |
Wen Tao Li
DFI | Director of Finance/CFO | 41 | 19-12-31 |
Yanru Jia
BRD | Director/Board Member | 41 | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chi Kin Wong
BRD | Director/Board Member | 50 | 23-04-12 |
Ling Liu
BRD | Director/Board Member | 63 | 20-12-17 |
Tsz Wing Leung
BRD | Director/Board Member | 39 | 20-12-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.3 | -1.64% | 210,000 |
| 24-04-25 | 0.305 | -1.61% | 657,000 |
| 24-04-24 | 0.31 | +1.64% | 48,000 |
| 24-04-23 | 0.305 | -3.17% | 36,000 |
| 24-04-22 | 0.315 | -1.56% | 114,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
Modern Chinese Medicine Group Co Ltd is a China-based investment holding company that mainly produces Chinese patent medicines. The Company mainly provides over-the-counter (OTC) and prescribed medicine intended for use by the middle-aged and elderly people. The Company's main products are Vigour and Vitality Supplement Pill, Circulation Enhancement Pill, Cardiotonic Enhancement Capsule, Kidney Invigoration Pill, Heart Wellness Capsule, Menstrual Discomfort Relief Pill, Liver Detox Tablet, Additional Ingredient Huoxiang ZhengQi Pill and Fever-removing and Detoxremoving Pill. The Company is also engaged in the production of other traditional Chinese medicines designed to treat or relieve other conditions such as psychological, respiratory, and pediatric conditions. The Company mainly conducts business within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.76% | 22.99M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 1643 Stock
